Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A diagnostic and therapeutic secreted target protein that is upregulated in a subset of human patients with Osteoarthritis. It is a strong regulatory candidate for the transformation of maintenance chondrocytes into digestive aggravators of OA. More
The present invention relates to osteoarthritis (OA) and methods of OA diagnosis and treatment via the findings of a genome-wide analysis of dysregulated genes in OA. More
Kit for diagnosis and prognosis of bladder cancer in urine More
Blood genetic marker for predicting restenosis after the use of heart stents More
Direct gene amplification using AnyDirect solution gives reliable results from crude biospecimens without DNA isolation or any instrument. More
Comparative Gene Expression Profiles are Diagnostic for Improved Outcomes and Medical Management of Multiple Myeloma More
Use of cDNA microarrays to facilitate the identification of pulmonary neuroendocrine tumors More
These gene chips detect the over-expression of the cancer-related extracellular matrix (ECM) modifier proteins Anakin and Bromodomain 4 (Brd4). More
PharmiGene Inc.:Technology associated with the PG 5801 DNA Detection Kit and the PG 5801 FastGel Kit
Technology associated with PharmiGene's PG 5801 DNA Detection Kit and the PG 5801 FastGel Kit, kits to determine the risk of Allopurinol-induced severe cutaneous adverse reaction (SCAR). More
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us